傲農生物(603363.SH)擬與許水根向建德鑫欣增資合計5500萬元
格隆匯11月7日丨傲農生物(603363.SH)公佈,為了公司在浙江省生豬養殖業務的發展,充分發揮雙方業務優勢,促進做大做強,公司於2019年11月7日與許水根、韓金良簽署了《建德市鑫欣生豬養殖有限公司股權合作協議》,公司擬與目標公司原股東許水根共同向建德市鑫欣生豬養殖有限公司(以下簡稱“建德鑫欣”或“目標公司”)增資5500萬元,其中公司以人民幣5200萬元對目標公司進行增資,認購目標公司5200萬元新增註冊資本。本次增資完成後,目標公司註冊資本由原1000萬元增加至6500萬元,公司持有目標公司80%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.